TRAITEMENT DES MALADIES VASCULAIRES PERIPHERIQUES, DES NEUROPATHIES DU SYSTEME NERVEUX PERIPHERIQUES ET DES NEUROPATHIES DU SYSTEME NERVEUX AUTONOME

METHOD OF TREATING PERIPHERAL VASCULAR DISEASES, PERIPHERAL NEUROPATHIES, AND AUTONOMIC NEUROPATHIES

Abrégé français

L'invention concerne une méthode de traitement destinée à un patient souffrant d'une maladie vasculaire périphérique, de neuropathies du système nerveux périphérique ou de neuropathies du système nerveux autonome, comprenant l'administration d'un inhibiteur de cGMP PDE5 tel que le sildenafil. Cette méthode convient particulièrement pour les patients souffrant d'un ulcère diabétique du pied, d'un syndrome de Raynaud, d'un syndrome Crest, d'une érythromatose, de maladies rhumatoïdes, de rétinopathies diabétiques et d'onychomycoses. L'invention concerne également l'administration d'un inhibiteur de cGMP PDE5 en tant qu'agent de prévention à des patients présentant une prédisposition à une maladie vasculaire périphérique, une neuropathie périphérique ou une neuropathie du système nerveux autonome.

Abrégé anglais

A method of treating a patient suffering from peripheral vascular disease,
peripheral neuropathies, or autonomic neuropathies by administering a cGMP
PDE5 inhibitor such as sildenafil. The method is particularly applicable to
patients suffering from diabetic foot ulcers, Raynaud's Phenomenon, CREST
Syndrome, erythromatosis, rheumatoid diseases, diabetic retinopathies and
onychiomycosis. According to the present invention, a cGMP PDE5 inhibitor may
be administered as a prophylactic to patients predisposed to develop a
peripheral vascular disease, peripheral neuropathy or autonomic neuropathy.

Revendications

What I claim is:
1. A method of treating the disease of a type selected from peripheral
vascular
diseases, peripheral neuropathies, and autonomic neuropathies, comprising
administering an effective amount of a pharmaceutical composition comprising a
cGMP PDES inhibitor or a derivative or salt thereof.
2. A method of treating a disease according to claim 1 wherein said disease is
selected from the group consisting of Raynaud's Phenomenon, CREST syndrome,
erythromatosis, rheumatoid diseases and diabetic retinopathies.
3. A method of treating onychiomycosis comprising administering an effective
amount of a pharmaceutical composition comprising a cGMP PDES inhibitor or a
derivative or salt thereof.
4. A method of treating a patient suffering from diabetic foot ulcers which
comprises treating said patient with an effective amount of a pharmaceutical
composition comprising a cGMP PDES inhibitor or a derivative or salt thereof.
5. A method of preventing the formation of foot ulcers in a patient suffering
from
the disease diabetes, the method comprising administering to said patient an
effective
amount of a pharmaceutical composition comprising a cGMP PDES inhibitor or a
derivative or salt thereof.
13

6. A method of manufacturing a diabetic foot ulcer therapeutic comprising
providing an effective ingredient selected from the group consisting of a cGMP
PDES
inhibitor, a derivative thereof, and a salt thereof and combining said
effective
ingredient with a suitable carrier for administration to a patient.
7. A method according to claim 4 or 5, wherein the cGMP PDE 5 inhibitor is
sildenafil.
14

Description

CA 02414352 2002-12-24
WO 02/02118 PCT/USO1/41202
METHOD